Dapagliflozin: where does it fit in the treatment of type 2 diabetes?

Bibliography

• International Diabetes Federation. Diabetes prevalence. Available from: http://www.idf.org/diabetes-prevalence. [Accessed 16 May 2009]
   Google Scholar
• Klein R, Klein BEK. Vision disorders in diabetes. In: 2nd edition. Diabetes in America. Bethesda, MD: National Diabetes Data Group, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995. p. 293-338
   Google Scholar
• Warram JH, Gearin G, Laffel L, et al. Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol 1996;7:930-7
   PubMed Web of Science ®Google Scholar
• Reenders K, de Nobel E, van den Hoogen HJ, et al. Diabetes and its long-term complications in general practice: a survey in a well-defined population. Fam Pract 1993;10:169-72
   Google Scholar
• Lee WL, Cheung AM, Cape D, et al. Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies. Diabetes Care 2000;23:962-8
   PubMed Web of Science ®Google Scholar
• Booth GL, Kapral MK, Fung K, et al. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 2006;368:29-36
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
   PubMed Web of Science ®Google Scholar
• Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Eng J Med 2005;353:2643-53
   PubMed Web of Science ®Google Scholar
• Holman RR, Rahman T, Ismail AA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
   PubMed Web of Science ®Google Scholar
• Ray KR, Seshasai SRK, Sivakumaran R, et al. Effect of intensive control of glucose on cardiovascular outcomes and death inpatients with diabetes mellitus: a meta-analysis of randomized controlled trials. Lancet 2009;373:1765-2
   PubMed Web of Science ®Google Scholar
• Harris M. Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care 2000;23:754-58
   PubMed Web of Science ®Google Scholar
• Silverman M. Structure and function of hexose transporters. Annu Rev Biochem 1991;60:757-94
   PubMed Web of Science ®Google Scholar
• Wright EM. Renal Na(+) – glucose cotransporters. Am J Physiol Renal Physiol 2001;280(1):F10-8
   PubMed Web of Science ®Google Scholar
• Thomson AB, Wild G. Adaptation of intestinal nutrient transport in health and disease. Dig Dis Sci 1997;42(3);453-88
   PubMed Web of Science ®Google Scholar
• Santer R, Kinner M, Lassen CL, et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 2003;14:2873-82
   PubMed Web of Science ®Google Scholar
• Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007;261(1):32-43
   PubMed Web of Science ®Google Scholar
• Kanai Y, Lee WS, You G, et al. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994;93(1):397-404
   PubMed Web of Science ®Google Scholar
• Hediger MA, Rhoads DB. Molecular physiology of sodium-glucose cotransporters. Physiol Rev 1994;74(4):993-1026
   PubMed Web of Science ®Google Scholar
• Francis J, Zhang J, Farhi A, et al. A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria. Nephrol Dial Transplant 2004;19:2394-6
   PubMed Web of Science ®Google Scholar
• Scholl-Burgi S, Santer R, Ehrich JH. Long-term outcome of renal glucosuria type O: the original patient and his natural history. Nephrol Dial Transplant 2004;19:2394-6
   PubMed Web of Science ®Google Scholar
• Oemar BS, Byrd DJ, Brohehl J. Complete absence of tubular glucose reabsorption: a new type of renal glucosuria (type 0). Clin Nephrol 1987;27:156-60
   PubMed Web of Science ®Google Scholar
• Desjeux J-F, Turk E, Wright E. Congenital selective Na/D-glucose cotransport defects leading to renal glucosuria, congenital selective intestinal malabsorption of glucose, galactose. In: Scriver CR, Beaudet al, Sly WS, Valle D, editors, The metabolic basis of inherited disease. 7th edition. New York, McGraw-Hill; 1994. p. 3563-80
   Google Scholar
• van den Heuvel LP, Assink K, Willemsen M, et al. Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum Genet 2002;111:544-7
   PubMed Web of Science ®Google Scholar
• Calado J, et al. Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting. Kidney Int 2006;69:852-5
   PubMed Web of Science ®Google Scholar
• Ehrenkranz JRL, Lewis NG, Kahn CR. Phlorizin: a review. Diabetes Metab Res Rev 2005;21:31-8
   PubMed Web of Science ®Google Scholar
• Keller DM, Lotspeich WD. Effect of phlorizin on the osmotic behaviour of mitochondria in isotonic sucrose. J Biol Chem 1959;234:991-4
   PubMed Web of Science ®Google Scholar
• Alvarado FC, Crane RK. Phlorizin as a competitive inhibitor of the active transport of sugars by hamster small intestine in vitro. Biochim Biophys Acta 1962;56:170-2
   PubMedGoogle Scholar
• Idris I, Donnelly R. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab 2009;11:79-88
   PubMed Web of Science ®Google Scholar
• Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008;57:1723-9
   PubMed Web of Science ®Google Scholar
• Komoroski B, Vachharajani N, Feng Y, et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol 2009;85(5):513-9
   Google Scholar
• Devenny J, Harvey S, Roony S, et al. The effect of dapagliflozin (BMS-512148), a selective SGLT2 inhibitor, on body weight in diet-induced obese rats. North American Association for the Study of Obesity Annual Meeting 2007;15(suppl 9):A121
   Google Scholar
• Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008;51:1145-9
   PubMed Web of Science ®Google Scholar
• Li L, Komoroski B, Boulton D, et al. Safety, Pharmacokinetics, and pharmacodynamics of dapagliflozin (BMS-512148), a selective SGLT2 inhibitor, in an ascending, placebo-controlled, single-dose study in healthy adult participants. June 5 – 9, 2009, New Orleans USA EASD meeting, #0764 2007
   Google Scholar
• List J, Woo VC, Morales E, et al. Sodium-glucose co-transport inhibition with dapagliflozin in type 2 diabetes mellitus. Diabetes Care 2009;32:650-7
   PubMed Web of Science ®Google Scholar
• Wilding PH, Norwood P, et al. Dapagliflozin Pilot Study in Insulin-Resistant T2DM Patients. American Diabetes Association Annual Meeting June 5 – 9, 2009, New Orleans USA, 482P
   Google Scholar
• Carlson GF, Tou CKP, Darjkh S, et al. Dapagliflozin was not observed to prolong the QTc in a thorough QT/QTc Study. American Diabetes Association Annual Meeting June 5 – 9, 2009, New Orleans USA, 483P
   Google Scholar
• Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2008;31:1-11
   Web of Science ®Google Scholar
• Pharmacologic management of type 2 diabetes. Can J Diabetes 2008;32 (suppl 1):S53-61
   Web of Science ®Google Scholar
• Woo V. Important differences: Canadian Diabetes Association 2008 clinical practice guidelines and the consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52:552-3
   PubMed Web of Science ®Google Scholar
• Home PD, Pocock SJ, Beck-Nielsen, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;273(9681);2125-2135
   Google Scholar